Suppr超能文献

应用 DNA 微阵列技术监测所罗门群岛疟原虫对氯喹和磺胺多辛-乙胺嘧啶的抗药性。

Monitoring of malaria parasite resistance to chloroquine and sulphadoxine-pyrimethamine in the Solomon Islands by DNA microarray technology.

机构信息

Swiss Tropical and Public Health Institute, Department of Medical Parasitology and Biology of Infection, Department of Epidemiology and Public Health, Socinstrasse 57, 4002 Basel, Switzerland.

出版信息

Malar J. 2010 Oct 6;9:270. doi: 10.1186/1475-2875-9-270.

Abstract

BACKGROUND

Little information is available on resistance to anti-malarial drugs in the Solomon Islands (SI). The analysis of single nucleotide polymorphisms (SNPs) in drug resistance associated parasite genes is a potential alternative to classical time- and resource-consuming in vivo studies to monitor drug resistance. Mutations in pfmdr1 and pfcrt were shown to indicate chloroquine (CQ) resistance, mutations in pfdhfr and pfdhps indicate sulphadoxine-pyrimethamine (SP) resistance, and mutations in pfATPase6 indicate resistance to artemisinin derivatives.

METHODS

The relationship between the rate of treatment failure among 25 symptomatic Plasmodium falciparum-infected patients presenting at the clinic and the pattern of resistance-associated SNPs in P. falciparum infecting 76 asymptomatic individuals from the surrounding population was investigated. The study was conducted in the SI in 2004. Patients presenting at a local clinic with microscopically confirmed P. falciparum malaria were recruited and treated with CQ+SP. Rates of treatment failure were estimated during a 28-day follow-up period. In parallel, a DNA microarray technology was used to analyse mutations associated with CQ, SP, and artemisinin derivative resistance among samples from the asymptomatic community. Mutation and haplotype frequencies were determined, as well as the multiplicity of infection.

RESULTS

The in vivo study showed an efficacy of 88% for CQ+SP to treat P. falciparum infections. DNA microarray analyses indicated a low diversity in the parasite population with one major haplotype present in 98.7% of the cases. It was composed of fixed mutations at position 86 in pfmdr1, positions 72, 75, 76, 220, 326 and 356 in pfcrt, and positions 59 and 108 in pfdhfr. No mutation was observed in pfdhps or in pfATPase6. The mean multiplicity of infection was 1.39.

CONCLUSION

This work provides the first insight into drug resistance markers of P. falciparum in the SI. The obtained results indicated the presence of a very homogenous P. falciparum population circulating in the community. Although CQ+SP could still clear most infections, seven fixed mutations associated with CQ resistance and two fixed mutations related to SP resistance were observed. Whether the absence of mutations in pfATPase6 indicates the efficacy of artemisinin derivatives remains to be proven.

摘要

背景

在所罗门群岛(SI),有关抗疟药物耐药性的信息很少。分析与耐药相关的寄生虫基因中的单核苷酸多态性(SNPs)是替代经典的耗时耗力的体内研究来监测耐药性的潜在方法。pfmdr1 和 pfcrt 中的突变表明对氯喹(CQ)的耐药性,pfdhfr 和 pfdhps 中的突变表明对磺胺多辛-乙胺嘧啶(SP)的耐药性,pfATPase6 中的突变表明对青蒿素衍生物的耐药性。

方法

研究了 25 名在诊所就诊的有症状的恶性疟原虫感染患者的治疗失败率与周围人群中 76 名无症状个体感染的恶性疟原虫中与耐药相关的 SNP 模式之间的关系。该研究于 2004 年在所罗门群岛进行。招募了在当地诊所经显微镜确认患有恶性疟原虫疟疾的患者,并给予 CQ+SP 治疗。在 28 天的随访期间估计了治疗失败的发生率。同时,使用 DNA 微阵列技术分析了来自无症状社区样本中与 CQ、SP 和青蒿素衍生物耐药相关的突变。确定了突变和单倍型频率以及感染的多重性。

结果

体内研究显示 CQ+SP 治疗恶性疟原虫感染的疗效为 88%。DNA 微阵列分析表明寄生虫群体的多样性较低,98.7%的病例存在一种主要单倍型。它由 pfmdr1 位置 86、pfcrt 位置 72、75、76、220、326 和 356 以及 pfdhfr 位置 59 和 108 的固定突变组成。在 pfdhps 或 pfATPase6 中未观察到突变。平均感染的多重性为 1.39。

结论

这项工作首次提供了在所罗门群岛恶性疟原虫耐药性标志物的见解。获得的结果表明,在社区中循环的恶性疟原虫群体非常同质。尽管 CQ+SP 仍能清除大多数感染,但观察到与 CQ 耐药相关的七个固定突变和与 SP 耐药相关的两个固定突变。pfATPase6 中不存在突变是否表明青蒿素衍生物的疗效仍有待证实。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88ff/2959069/6031ca45ed44/1475-2875-9-270-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验